Antigen identification for HLA class I–and HLA class II–restricted T cell receptors using cytokine-capturing antigen-presenting cells

MN Lee, M Meyerson - Science immunology, 2021 - science.org
… in disease contexts such as cancer and natural/vaccine-elicited … sets due to the high
costs of peptide synthesis (15, 16). … 1A) and uses a cytokine readout to pinpoint T celltargeted

Targeting dendritic cells to advance cross-presentation and vaccination outcomes

C Macri, D Jenika, C Ouslinis, JD Mintern - Seminars in Immunology, 2023 - Elsevier
… network of specialised antigen-presenting cells that are critical … designed to elicit effective
cross-presentation for CD8 + T cell … DEC205-targeted DC vaccination elicits protection against …

[PDF][PDF] Recent advances in peptide-based nanovaccines for re-emerging and emerging infectious diseases

F Orosco - J. Adv. Biotechnol. Exp. Ther, 2024 - researchgate.net
… They have shown the ability to elicit robust immune responses, … Synthetic nanoparticles
predominantly enhance internalization by interacting structurally with antigen-presenting cells (…

Biomembrane-based nanostructures for cancer targeting and therapy: from synthetic liposomes to natural biomembranes and membrane-vesicles

J Wang, M Zhu, G Nie - Advanced drug delivery reviews, 2021 - Elsevier
cellular membranes and extracellular vesicles in anti-cancer therapies. While synthetic
“intelligent” modules to respond, regulate, and target tumor cells and the microenvironment …

In vitro and in vivo evaluation of DC-targeting PLGA nanoparticles encapsulating heparanase CD4+ and CD8+ T-cell epitopes for cancer immunotherapy

XD Tang, KL Lü, J Yu, HJ Du, CQ Fan… - Cancer Immunology …, 2022 - Springer
… ensure efficient delivery to antigen-presenting cells. Here, we … to elicit effective and safe
T-cell-mediated antitumor immunity … TLR7 can be activated by several synthetic agonists, such as …

Leveraging biomaterials for enhancing T cell immunotherapy

Z Liao, W Zhang, H Zheng, Y Wang, J Yu, H Li… - Journal of Controlled …, 2022 - Elsevier
… ) on antigen-presenting cells (APCs). To date, vast groups of … engineered cellular platforms
or synthetic biomaterials. … components elicited 6.4-fold higher antitumor responses compared …

A DNA vaccine that encodes an antigen-presenting cell-specific heterodimeric protein protects against cancer and influenza

R Braathen, HCL Spång, DM Hinke, J Blazevski… - … Therapy-Methods & …, 2020 - cell.com
… two different antigens induced antibody and T cell responses against either of the two …
tested for their ability to induce protection against MOPC315 myeloma cells. BALB/c mice were …

NKT agonist-antigen conjugates as cancer vaccines

BJ Compton, GF Painter - Critical Reviews™ in Oncogenesis, 2024 - dl.begellhouse.com
… of CD40L that activate antigen-presenting cells (APCs) … cell targeted agonist-antigen
conjugate vaccines can elicit … IgG antibody response elicited by a fully synthetic two-component …

A natural IgM hitchhiking strategy for delivery of cancer nanovaccines to splenic marginal zone B cells

H Wang, X Wu, Y Sun, A Liu, Y He, Z Xu, Y Lu… - Journal of Controlled …, 2024 - Elsevier
… B cell-targeted … to provoke specific antitumor immunity has evoked great interest in recent
years [3,4]. Efficient antigens presentation to antigen-presenting cells (APCs) such as B cells, …

Extracellular vesicles mediate B cell immune response and are a potential target for cancer therapy

T Kato, JF Fahrmann, SM Hanash, J Vykoukal - Cells, 2020 - mdpi.com
… relationships between EVs, B cells, and other antigen-presenting cells, especially in relation
… from B cells can also be elicited by simple MHC-II crosslinking. B cell synthesis of EVs is …